Abstract
Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Adolescent Psychiatry
Title:Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis
Volume: 2 Issue: 2
Author(s): Kate V. Hardy and Rachel Loewy
Affiliation:
Keywords: Adolescents, clinical high risk, cognitive behavioral therapy, psychosis, psychosocial interventions
Abstract: Cognitive Behavioral Therapy (CBT) is an established adjunctive treatment for schizophrenia with a growing evidence base. More recently, CBT has been applied to individuals identified as being at risk for developing psychosis in an attempt to delay or prevent a transition to psychosis, to reduce symptoms and improve functioning. CBT has also been employed effectively with adolescents in the treatment of depression, post traumatic stress disorder (PTSD), anxiety disorders and eating disorders. This paper reviews the evidence for the use of CBT with the clinical high risk for psychosis population and addresses adaptations to the approach for use specifically with adolescents.
Export Options
About this article
Cite this article as:
Hardy Kate V. and Loewy Rachel, Cognitive Behavioral Therapy for Adolescents at Clinical High Risk for Psychosis , Adolescent Psychiatry 2012; 2 (2) . https://dx.doi.org/10.2174/2210676611202020172
DOI https://dx.doi.org/10.2174/2210676611202020172 |
Print ISSN 2210-6766 |
Publisher Name Bentham Science Publisher |
Online ISSN 2210-6774 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Carbon Monoxide and the Pancreas
Current Pharmaceutical Biotechnology Metformin and Energy Metabolism in Breast Cancer: From Insulin Physiology to Tumour-initiating Stem Cells
Current Molecular Medicine Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets Editorial [ Hot Topic:Biology in Anticancer Treatment (Guest Editor: Bruno Vincenzi)]
Current Cancer Drug Targets Effects of Melatonin on Peripheral Nerve Regeneration
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal Twist-BRD4 Complex: Potential Drug Target for Basal-like Breast Cancer
Current Pharmaceutical Design The Roles of Vitamin D and Its Analogs in Inflammatory Diseases
Current Topics in Medicinal Chemistry Bile Acids as Novel Pharmacological Agents: The Interplay Between Gene Polymorphisms, Epigenetic Factors and Drug Response
Current Pharmaceutical Design The Metabolic Syndrome and HIV Infection
Current Pharmaceutical Design Molecularly Imprinted Sol-Gel Materials for Medical Applications
Current Topics in Medicinal Chemistry The Design and Development of Deferiprone (L1) and Other Iron Chelators for Clinical Use: Targeting Methods and Application Prospects
Current Medicinal Chemistry The Hypothalamus and Obesity
Recent Patents on CNS Drug Discovery (Discontinued) Treatment of Anaplastic Thyroid Cancer: Is there a Role for PPARγ Agonists?
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery PIM1 Kinase as a Target in Prostate Cancer: Roles in Tumorigenesis, Castration Resistance, and Docetaxel Resistance
Current Cancer Drug Targets Alterations of Sex Differentiation in Males: From Candidate Genes to Diagnosis and Treatments
Current Pharmaceutical Design Patent Annotations
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Sam68 Promotes the Progression of Human Breast Cancer through inducing Activation of EphA3
Current Cancer Drug Targets Somatostatin Receptor-Targeted Anti-Cancer Therapy
Current Drug Delivery